Ipilimumab Improves Overall Survival in Previously Treated, Advanced Melanoma Patients with Good and Poor Prognostic Factors

被引：0
|
作者：
O'Day, Steven J. [1 ,2 ]
McDermott, David F. [10 ]
Urba, Walter J. [4 ]
Wolchok, Jedd D. [5 ]
Robert, Caroline [6 ]
Haanen, John B. [7 ]
Dummer, Reinhard [8 ]
Messina, Marianne [9 ]
Hoos, Axel [9 ]
Hodi, F. Stephen [3 ]
机构：
[1] Angeles Clin, Los Angeles, CA USA
[2] Res Inst, Los Angeles, CA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Earle A Chiles Res Inst, Portland, OR USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Inst Gustave Roussy, Villejuif, France
[7] Netherlands Canc Inst, Amsterdam, Netherlands
[8] Univ Hosp, Zurich, Switzerland
[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[10] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2010年 / 33卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：905 / 906
页数：2
相关论文
共 50 条
  • [31] Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Chapman, Paul B.
    Jayaprakasam, Vetri Sudar
    Panageas, Katherine S.
    Callahan, Margaret
    Postow, Michael A.
    Shoushtari, Alexander N.
    Wolchok, Jedd D.
    Warner, Allison Betof
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [32] IpilimumabIn Previously Treated Patients with Advanced Melanoma
    Mark Sanford
    BioDrugs, 2012, 26 : 185 - 193
  • [33] PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED OVARIAN-CARCINOMA
    LUND, B
    WILLIAMSON, P
    ANNALS OF ONCOLOGY, 1991, 2 (04) : 281 - 287
  • [34] Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
    Ahmad, Saif S.
    Qian, Wendi
    Ellis, Sarah
    Mason, Elaine
    Khattak, Muhammad A.
    Gupta, Avinash
    Shaw, Heather
    Quinton, Amy
    Kovarikova, Jarmila
    Thillai, Kiruthikah
    Rao, Ankit
    Board, Ruth
    Nobes, Jenny
    Dalgleish, Angus
    Grumett, Simon
    Maraveyas, Anthony
    Danson, Sarah
    Talbot, Toby
    Harries, Mark
    Marples, Maria
    Plummer, Ruth
    Kumar, Satish
    Nathan, Paul
    Middleton, Mark R.
    Larkin, James
    Lorigan, Paul
    Wheater, Matthew
    Ottensmeier, Christian H.
    Corrie, Pippa G.
    MELANOMA RESEARCH, 2015, 25 (05) : 432 - 442
  • [35] CONDITIONAL SURVIVAL PROBABILITIES FOR PREVIOUSLY UNTREATED ADVANCED MELANOMA PATIENTS RECEIVING IPILIMUMAB: MODEL BASED ANALYSIS
    Lee, D.
    Kotapati, S.
    Porter, J.
    Hertel, N.
    Zagorska, A.
    Hatswell, A. J.
    VALUE IN HEALTH, 2015, 18 (03) : A195 - A195
  • [36] MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors
    Neven, Patrick
    Johnston, Stephen
    Toi, Masakazu
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla
    Llombart-Cussac, Antonio
    Sledge, George W., Jr.
    CANCER RESEARCH, 2020, 80 (04)
  • [37] Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma
    Postow, Michael Andrew
    Chasalow, Scott D.
    Yuan, Jianda
    Kuk, Deborah
    Panageas, Katherine S.
    Cheng, Michael
    Shahabi, Vafa
    Berman, David Mark
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone
    Koller, Kristian M.
    Mackley, Heath B.
    Liu, Jason
    Wagner, Henry
    Talamo, Giampaolo
    Schell, Todd D.
    Pameijer, Colette
    Neves, Rogerio I.
    Anderson, Bryan
    Kokolus, Kathleen M.
    Mallon, Carol A.
    Drabick, Joseph J.
    CANCER BIOLOGY & THERAPY, 2017, 18 (01) : 36 - 42
  • [39] CONDITIONAL SURVIVAL (CS) PROBABILITIES FOR ADVANCED MELANOMA PATIENTS TREATED WITH IPILIMUMAB: MODEL BASED ANALYSIS
    Lee, D.
    Kotapati, S.
    Gueron, B.
    Bapat, U.
    Batty, A. J.
    VALUE IN HEALTH, 2013, 16 (07) : A398 - A398
  • [40] Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine
    Hersh, E.
    Weber, J.
    Powderly, J.
    Pavlik, A.
    Nichol, G.
    Yellin, M.
    Cranmer, L.
    Urba, W.
    O'Day, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345